China Single Photon Emission Computed Tomography Market Size, Share, and Future Opportunities by 2035
Single Photon Emission Computed Tomography (SPECT) remains a cornerstone of non-invasive functional imaging throughout hospitals in China. As detailed in recent industry insights on the China Single Photon Emission Computed Tomography Market, the market's clinical utility spans cardiology, oncology, neurology, and endocrinology, while its broader adoption remains closely tied to the stability of regional radioisotope supply chains.
Primary Clinical Utility Across Key Specialties
-
Nuclear Cardiology: Myocardial Perfusion Imaging (MPI) represents one of the highest-volume clinical applications for SPECT in China. It provides critical assessments of coronary artery disease, ischemia, and myocardial viability, offering a cost-effective alternative to invasive coronary angiography.
-
Oncology and Bone Scans: Whole-body bone scintigraphy utilizing Technetium-99m ($^{99\text{m}}\text{Tc}$)-labeled diphosphonates is widely deployed for detecting bone metastases from lung, prostate, and breast cancers.
-
Endocrinology and Thyroid Scans: Iodine-131 ($^{131}\text{I}$) and $^{99\text{m}}\text{Tc}$ imaging are routinely used to evaluate thyroid nodules, hyperthyroidism, and ectopic thyroid tissue across municipal hospitals.
Radioisotope Supply Chain Dynamics
The widespread usage of SPECT systems depends fundamentally on the reliable supply of medical radioisotopes, particularly Molybdenum-99 ($^{99}\text{Mo}$), the parent isotope of Technetium-99m ($^{99\text{m}}\text{Tc}$). Historically dependent on overseas nuclear reactors, China has taken major strategic steps toward domestic radioisotope self-sufficiency.
National nuclear energy organizations are developing domestic research reactors, cyclotrons, and commercial processing facilities to ensure a stable supply of key diagnostic isotopes. This localization strategy mitigates global supply disruption risks and lowers radionuclide procurement costs for domestic hospitals.
Integration of Novel Radiopharmaceuticals
Alongside infrastructure development, Chinese researchers are actively developing novel targeted radiopharmaceuticals. The introduction of new SPECT tracers designed for specific molecular targets—such as fibroblast activation protein inhibitors (FAPI) and somatostatin receptor analogues—is expanding the diagnostic capabilities of SPECT/CT beyond classical perfusion and skeletal scans, opening new avenues for personalized medicine.
